Clinical trial
Study of Individualized Amonafide to Treat Prostate Cancer
NCT00087854 · Xanthus Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00087854 |
|---|---|
| Title | Study of Individualized Amonafide to Treat Prostate Cancer |
| Official title | Dose-Defining Study of a NAT2 Phenotype-Based Dosing Regimen of Intravenous Amonafide L-Malate Administered Weekly in Men With Androgen-Independent Prostate Cancer (AIPC) |
| Lead sponsor | Xanthus Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Amonafide L-malate (drug) |
| Enrollment | 40 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Jul 16, 2004 |
| Last update posted | Apr 23, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: